Meanwhile, concurrent administration of the angiotensin (1–7) antagonist with olmesartan (30 mg/kg) reduced the antitumor effect of olmesartan; the tumor weight in this group was different from the EAC-control group, olmesartan (30 mg/kg) group and angiotensin (1–7) agonist group (Fig. 1B). The gene discussed is AGT; the disease is neoplasm.